Clinical Trials Logo

Carcinoma clinical trials

View clinical trials related to Carcinoma.

Filter by:
  • Withdrawn  
  • Page 1 ·  Next »

NCT ID: NCT06145399 Withdrawn - Breast Cancer Clinical Trials

A Study of 1 8F-FDHT PET/MRIScans in Women With Breast Cancer

Start date: October 24, 2023
Phase: Early Phase 1
Study type: Interventional

The purpose of this study is to see whether 18F-FDHT PET/MRI scans are an effective way of identifying AR-positive breast cancer.

NCT ID: NCT06090318 Withdrawn - Gastric Cancer Clinical Trials

Milademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With CDKN2A Loss

Start date: May 19, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

This is an open-label, single-arm, Phase 1b/2 study designed to evaluate the safety, tolerability, and preliminary efficacy of milademetan in combination with atezolizumab in patients with advanced solid tumors with confirmed homozygous CDKN2A loss and WT TP53 who have progressed on or are refractory to prior PD-1/PD-L1 inhibitor therapy and who, in the opinion of the Investigator, are unlikely to tolerate or derive clinically meaningful benefit from other therapy. This study will determine the recommended dose of milademetan when given in combination with atezolizumab (the combination RP2D) using a dose de-escalation safety assessment cohort (Phase 1b). Following identification of the combination RP2D, the safety profile and preliminary anti-tumor activity of the combination RP2D will be evaluated in a larger population in a dose expansion cohort (Phase 2).

NCT ID: NCT06006286 Withdrawn - Clinical trials for Metastatic Hepatocellular Carcinoma

A Study Evaluating Atezolizumab and Bevacizumab Plus ADI-PEG 20 in Patients With Locally Advanced / Metastatic Hepatocellular Carcinoma

Start date: August 8, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

To learn about the safety and tolerability of atezolizumab, bevacizumab, and ADI-PEG 20 when given in combination to patients with locally advanced or metastatic liver cancer

NCT ID: NCT05967286 Withdrawn - Clinical trials for Anatomic Stage III Breast Cancer AJCC v8

Olaparib and Alpelisib for Treatment of Metastatic Breast Cancer, A ComboMATCH Treatment Trial

Start date: October 23, 2023
Phase: Phase 2
Study type: Interventional

This phase II ComboMATCH treatment trial studies the effect of adding a drug called BYL719 (alpelisib) to the usual treatment of olaparib in patients with breast cancer that has spread from where it first started (breast) to other places in the body (metastatic). Olaparib is an inhibitor of PARP, an enzyme that helps repair DNA when it becomes damaged. Blocking PARP may help keep tumor cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy. Alpelisib blocks certain proteins, which may help keep tumor cells from growing and may kill them. It is a type of kinase inhibitor. Giving alpelisib in combination with olaparib may be able to improve treatment results for patients with metastatic breast cancer.

NCT ID: NCT05935774 Withdrawn - Clinical trials for Stage IV Lung Cancer AJCC v8

OT-101 in Combination With Atezolizumab for the Treatment of Metastatic or Recurrent Non-Small Cell Lung Cancer

Start date: December 1, 2023
Phase: Phase 2
Study type: Interventional

This phase II trial tests how well trabedersen (OT-101) in combination with atezolizumab works in treating patients with non-small cell lung cancer (NSCLC) that has spread from where it first started (lung) to other places in the body (metastatic) or has come back after a period of improvement (recurrent). OT-101 is a transforming growth factor (TGF)-beta2 specific drug. TGF-beta2, a cytokine that is often overexpressed in various malignant tumors, may play an important role in promoting the growth, progression and migration of tumor cells. OT-101 binds to the TGF-beta2 receptor causing inhibition of protein production, thereby decreasing TGF-beta2 protein levels which may result in the inhibition of tumor cell growth and migration. Atezolizumab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. Giving OT-101 and atezolizumab together may be an effective treatment for patients with metastatic or recurrent NSCLC.

NCT ID: NCT05886257 Withdrawn - Clinical trials for Hepatocellular Carcinoma

Candonilimab Plus Bevacizumab for Patients With Advanced HCC Who Progressed on A+T

Start date: December 7, 2022
Phase: Phase 2
Study type: Interventional

To explore the efficacy and safety of candonilimab plus bevacizumab for patients with advanced hepatocellular carcinoma who progressed on atezolizumab plus bevacizumab.

NCT ID: NCT05774886 Withdrawn - Breast Cancer Clinical Trials

Implantable Microdevice for TNBC - Pilot Study

Start date: May 2023
Phase: Phase 1
Study type: Interventional

The goal of this research study is to evaluate the safety and feasibility of implanting and retrieving a microdevice that releases microdoses of a specific drug or combination of drugs as a possible tool to evaluate the effectiveness of several cancer drugs against early stage Triple Negative Breast Cancer (TNBC). The name of the intervention involved in this study is: Implantable Microdevice (IMD)

NCT ID: NCT05743777 Withdrawn - Clinical trials for Advanced Head and Neck Squamous Cell Carcinoma

PembROlizumab With or Without Microbial EcOsystem ThErapeutic 4 (MET4) in Advanced Head and Neck Squamous Cell Carcinoma

PROMOTE-HN
Start date: May 12, 2023
Phase: Phase 2
Study type: Interventional

The usual approach for patients who are not in a study is treatment with pembrolizumab, a type of immunotherapy drug. Immunotherapy works by allowing the immune system to detect your cancer and reactivate the immune response. This may help to slow down the growth of cancer and may cause cancer cells to die.

NCT ID: NCT05743270 Withdrawn - Clinical trials for Squamous Cell Carcinoma of Head and Neck

Study of RP3 in Combination With Nivolumab and Other Therapy in Patients With Locoregionally Advanced or Recurrent SCCHN

Start date: January 30, 2024
Phase: Phase 2
Study type: Interventional

This is a Phase 2, multicenter, open-label, 2-cohort (Locoregionally Advanced Cohort or Recurrent/Metastatic Cohort) study evaluating RP3 in combination with concurrent chemoradiation therapy (CCRT) followed by nivolumab (for the LA Cohort) or combined with chemotherapy and nivolumab (for the R/M Cohort) in patients with advanced, inoperable squamous cell carcinomas of the head and neck (SCCHN), including of the oral cavity, oropharynx, hypopharynx, larynx, or unknown primary.

NCT ID: NCT05729139 Withdrawn - Clinical trials for Squamous Cell Carcinoma

Cemiplimab/Peg-Interferon-α in Advanced CSCC

Start date: July 2023
Phase: Phase 1
Study type: Interventional

The primary purpose of this research study is to test the safety and possible harms of cemiplimab/peg-interferon-alpha, when it is given to participants at different dose levels. The researchers want to find out what effects (good and bad) cemiplimab/Peg-Interferon has on participants with advanced cutaneous squamous cell carcinoma (aCSCC) so that they can find the best dose to treat aCSCC and reduce side effects as much as possible.